These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6540782)

  • 1. Immunologic response to the treatment of Ehrlich ascites tumor with titanocene dichloride.
    Köpf-Maier P; Hesse A
    J Cancer Res Clin Oncol; 1984; 108(2):254-5. PubMed ID: 6540782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumour activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumour.
    Valadares MC; Ramos AL; Rehmann FJ; Sweeney NJ; Strohfeldt K; Tacke M; Queiroz ML
    Eur J Pharmacol; 2006 Mar; 534(1-3):264-70. PubMed ID: 16513106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis-diamminedichloroplatinum(II) and metallocene dichlorides.
    Köpf-Maier P; Wagner W; Liss E
    J Cancer Res Clin Oncol; 1981; 102(1):21-30. PubMed ID: 7199526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Titanocene dichloride--the first metallocene with cancerostatic activity.
    Köpf H; Köpf-Maier P
    Angew Chem Int Ed Engl; 1979 Jun; 18(6):477-8. PubMed ID: 111586
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tumor inhibition by metallocenes: effect of titanocene, zirconocene, and hafnocene dichlorides on Ehrlich ascites tumor in mice (author's transl)].
    Köpf-Maier P; Hesse B; Köpf H
    J Cancer Res Clin Oncol; 1980 Jan; 96(1):43-51. PubMed ID: 7188941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor inhibition by titanocene dichloride: first clues to the mechanism of action.
    Köpf-Maier P; Köpf H
    Naturwissenschaften; 1980 Aug; 67(8):415-6. PubMed ID: 7191057
    [No Abstract]   [Full Text] [Related]  

  • 7. [Molybdocene dichloride as an antitumor agent (author's transl)].
    Köpf-Maier P; Leitner M; Voigtländer R; Köpf H
    Z Naturforsch C Biosci; 1979 Dec; 34(12):1174-6. PubMed ID: 161840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micronucleated cells during the growth of the Ehrlich ascites tumour on spontaneous and by titanocenedichloride-induced conditions.
    Tarillion P; Taubert G; Nenning H
    Mutat Res; 1997 Mar; 389(2-3):213-8. PubMed ID: 9093386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of titanocene dihalides against a human colon carcinoma heterotransplanted to athymic mice.
    Köpf-Maier P; Moormann A; Köpf H
    Eur J Cancer Clin Oncol; 1985 Jul; 21(7):853-7. PubMed ID: 4043173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a Titanocene Dichloride derivative, Ti IV (C5H5)(2) NCS(2), on the haematopoietic response of Ehrlich tumour-bearing mice.
    Valadares MC; Queiroz ML
    Eur J Pharmacol; 2002 Mar; 439(1-3):35-42. PubMed ID: 11937090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early effects of cis-dichlorodiammine platinum (II) on tumor progression and programmed death of Ehrlich ascites carcinoma cells.
    Razin BV; Inzhevatkin EV; Nefedova VV; Egorova AB; Kazbanov VI; Nefedov VP
    Bull Exp Biol Med; 2001 Jun; 131(6):568-9. PubMed ID: 11586409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect.
    Köpf-Maier P; Wagner W; Hesse B; Köpf H
    Eur J Cancer (1965); 1981 Jun; 17(6):665-9. PubMed ID: 7308264
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergism between propolis and hyperthermal intraperitoneal chemotherapy with cisplatin on ehrlich ascites tumor in mice.
    Oršolić N; Car N; Lisičić D; Benković V; Knežević AH; Dikić D; Petrik J
    J Pharm Sci; 2013 Dec; 102(12):4395-405. PubMed ID: 24136132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro.
    Köpf-Maier P; Wagner W; Liss E
    J Cancer Res Clin Oncol; 1983; 106(1):44-52. PubMed ID: 6684118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor inhibition by metallocenes: antitumor activity of titanocene dihalides (C5H5)2TiX2 (X=F, Cl, Br, I, NCS) and their application in buffered solutions as a method for suppressing drug-induced side effects.
    Köpf-Maier P; Hesse B; Voigtländer R; Köpf H
    J Cancer Res Clin Oncol; 1980; 97(1):31-9. PubMed ID: 7400205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Titanocene modulation of cytokine imbalance induced by Ehrlich ascites tumour progression.
    Valadares MC; Klein SI; Queiroz ML
    Eur J Pharmacol; 2004 Oct; 503(1-3):203-8. PubMed ID: 15496315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor metallocenes: new developments and toxicologic features.
    Köpf-Maier P; Köpf H
    Anticancer Res; 1986; 6(2):227-33. PubMed ID: 3707060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor inhibition by titanocene complexes: activity against sarcoma 180.
    Köpf-Maier P; Preiss F; Marx T; Klapötke T; Köpf H
    Anticancer Res; 1986; 6(1):33-7. PubMed ID: 3954328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas.
    Köpf-Maier P
    J Cancer Res Clin Oncol; 1987; 113(4):342-8. PubMed ID: 3036884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histomorphologic changes in Jensen sarcoma following radiotherapy, titanocene dichloride treatment and combination therapy].
    Uhl J; Langrock K; Krieghoff B; Hambsch K
    Radiobiol Radiother (Berl); 1987; 28(1):51-7. PubMed ID: 3588859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.